[{"data":1,"prerenderedAt":272},["ShallowReactive",2],{"$f3inlikhhjwo4k":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":56,"top_diseases":82,"top_companies":114,"key_results":142,"trends":233,"previous_editions":242,"comparison":246,"highlighted_classes":268},1,"eular-2026","EULAR","eular","EULAR Congress 2026",2026,"Immunology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},3202,1089,169,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":18,"Phase 2\u002F3":20,"Phase 3":21},36,13,59,5,102,[23,27,31,34,37,40,43,46,50,53],{"name":24,"count":25,"share":26},"JAK1",118,11,{"name":28,"count":29,"share":30},"CD20",70,6,{"name":32,"count":33,"share":30},"TNFA",62,{"name":35,"count":36,"share":30},"IL-17A",60,{"name":38,"count":39,"share":20},"CD19",55,{"name":41,"count":42,"share":20},"IL1R1",54,{"name":44,"count":45,"share":20},"GR",52,{"name":47,"count":48,"share":49},"DHFR",44,4,{"name":51,"count":52,"share":49},"TS",41,{"name":54,"count":55,"share":49},"JAK3",39,[57,60,63,66,70,72,76,79],{"name":58,"count":59,"share":42},"Small molecules",591,{"name":61,"count":62,"share":55},"Monoclonal antibodies",430,{"name":64,"count":65,"share":18},"Non-antibody therapeutic proteins",139,{"name":67,"count":68,"share":69},"Bispecific antibodies",75,7,{"name":71,"count":39,"share":20},"Cell therapies",{"name":73,"count":74,"share":75},"Peptides",23,2,{"name":77,"count":78,"share":75},"Carbohydrate, lipid and polymer therapeutics",17,{"name":80,"count":81,"share":4},"Radiopharmaceuticals",14,[83,87,91,94,98,101,103,106,108,110],{"name":84,"count":85,"share":86},"rheumatoid arthritis (RA)",272,25,{"name":88,"count":89,"share":90},"systemic lupus erythematosus (SLE)",224,21,{"name":92,"count":93,"share":18},"psoriatic arthritis (PsA)",145,{"name":95,"count":96,"share":97},"systemic sclerosis (SSc)",98,9,{"name":99,"count":100,"share":30},"Sjögren's syndrome",65,{"name":102,"count":36,"share":30},"axial spondyloarthritis (axSpA)",{"name":104,"count":105,"share":20},"lupus nephritis (LN)",57,{"name":107,"count":42,"share":20},"interstitial lung disease (ILD)",{"name":109,"count":55,"share":49},"Autoimmune Myopathies",{"name":111,"count":112,"share":113},"giant cell arteritis (GCA)",38,3,[115,118,120,123,126,129,132,135,138,140],{"name":116,"count":117,"share":97},"Pfizer",97,{"name":119,"count":36,"share":30},"AbbVie",{"name":121,"count":122,"share":20},"Genentech",56,{"name":124,"count":125,"share":20},"Bayer",51,{"name":127,"count":128,"share":20},"Amgen",50,{"name":130,"count":131,"share":49},"GSK",48,{"name":133,"count":134,"share":49},"Johnson & Johnson",47,{"name":136,"count":137,"share":49},"Novartis",46,{"name":139,"count":52,"share":49},"AstraZeneca",{"name":141,"count":52,"share":49},"Sanofi",[143,152,159,167,174,181,188,196,204,213,220,227],{"title":144,"drug":145,"company":147,"phase":148,"disease":149,"finding":150,"url":151},"Obexelimab, a B Cell Inhibitor, in IgG4-Related Disease: Results From the Phase 3 INDIGO Trial",{"name":146,"slug":146},"obexelimab","Zenas BioPharma","Phase 3","IgG4-related disease (IgG4-RD)","Obexelimab reduced the risk of flare by 56% versus placebo (HR 0.443; 95% CI 0.277–0.711; p=0.0005).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQhX4nq8Fsi5Hxze2jAX5D2MnFidIVUfZVx0s8-f-Aljt0",{"title":153,"drug":154,"company":136,"phase":148,"disease":156,"finding":157,"url":158},"Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial",{"name":155,"slug":155},"secukinumab","polymyalgia rheumatica (PMR)","The risk of requiring escape or rescue treatment was reduced by 50% for both secukinumab doses compared to placebo (hazard ratios of 0.5; P\u003C0.001 for SEC-300 and P\u003C0.01 for SEC-150).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQhT4DGrZCjEuFN-8utV7Uzmbb60tjZqMdBAglaDy5fLS0",{"title":160,"drug":161,"company":163,"phase":148,"disease":164,"finding":165,"url":166},"Efficacy of nerandomilast in patients with autoimmune interstitial lung diseases and progressive pulmonary fibrosis in the FIBRONEER-ILD trial",{"name":162,"slug":162},"nerandomilast","Boehringer Ingelheim","pulmonary fibrosis (PF)","In the patients with autoimmune ILDs, both doses of nerandomilast had a nominally significant effect on the risk of death (HR vs placebo: 0.40 [95% CI: 0.17, 0.94] for 9 mg bid and 0.28 [95% CI: 0.11, 0.69] for 18 mg bid).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQme0xwNO82XaGYmWESVNRL72Li0Ir9bsAp3GCD4axtC10",{"title":168,"drug":169,"company":130,"phase":148,"disease":171,"finding":172,"url":173},"Mepolizumab Improves Remission Achievement and Duration, and OCS Sparing in Patients With EGPA with Comorbid Chronic Rhinosinusitis with Nasal Polyps: A Post Hoc Analysis of the MIRRA Study",{"name":170,"slug":170},"mepolizumab","eosinophilic granulomatosis with polyangiitis (EGPA)","Mepolizumab increased accrued duration in remission versus placebo (odds ratio (OR) [95% CI], 5.47 [1.45, 20.53], p=0.012), with 42% of patients treated with mepolizumab spending 12 or more weeks in remission compared with 4% with placebo.","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQovebkD8xVp4MKJ-2ZQeg-yEQPrL5qzP4os7Kx2F1dU80",{"title":175,"drug":176,"company":178,"phase":148,"disease":84,"finding":179,"url":180},"A Randomized Double-Blind Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of LNK01001 (zemprocitinib) in Patient with Moderate-to-Severe Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs (COURAGE-RA)",{"name":177,"slug":177},"zemprocitinib","Lynk Pharmaceuticals","Improvements in ACR70 (34.4% vs 7.5%), DAS28(CRP)\u003C2.6 (48.8% vs 12.6%), CDAI≤10 (61.4% vs 22.4%), and SDAI≤11 (63.7% vs 23.8%) remained significant (all p\u003C0.0001).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQiIXWjJlIz843vL8R0Y2loLvlhenhLssHxZH8KykCq160",{"title":182,"drug":183,"company":185,"phase":148,"disease":99,"finding":186,"url":187},"Efficacy and safety of Telitacicept in patients with Sjogren's disease: results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study",{"name":184,"slug":184},"telitacicept",null,"Compared to placebo, a statistically significant decrease in ESSDAI score from baseline at Week 24 was observed in Telitacicept 160 mg (LS Mean change: -4.4 vs -0.6, p\u003C0.0001) and Telitacicept 80 mg (LS Mean change: -3.0 vs -0.6, p\u003C0.0001).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQr-D6fnHsox1U95FPEYYD7xu3IamWYXuI_19jVPqLVIn0",{"title":189,"drug":190,"company":193,"phase":148,"disease":92,"finding":194,"url":195},"A Multicenter, Double-blind, Randomized, Parallel-arm Study to Compare Efficacy and Safety of BAT2506, a Golimumab Biosimilar, with the Golimumab Reference Product in Patients with Active Psoriatic Arthritis",{"name":191,"slug":192},"BAT2506","bat2506","Bio-Thera Solutions","Thirty-two subjects (4.5%) experienced serious TEAEs (5.4% in BAT2506 group, 4.3% in RP group, and 3.0% in RP-BAT2506 group).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQseNAu2WL78A-WFliysdbMoeGZUuLk9suFjKh34dcQgu0",{"title":197,"drug":198,"company":200,"phase":148,"disease":201,"finding":202,"url":203},"Rapid, Clinically Meaningful Improvement in Skin Disease with Brepocitinib in Dermatomyositis: Results from the Phase 3 VALOR Trial",{"name":199,"slug":199},"brepocitinib","Priovant Therapeutics","dermatomyositis (DM)","Brepocitinib 30 mg was also associated with increased achievement of CDASI-A response, with nominal statistical significance achieved at weeks 4, 8, and 12, and high rates of CDASI-A response with brepocitinib 30 mg (49.4% at Week 8; 56.8% at Week 12).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQsHmO-V7YyE2aSjraK6hg6xkH58gO4fthoy8bKkTIzut0",{"title":205,"drug":206,"company":209,"phase":148,"disease":210,"finding":211,"url":212},"Efficacy and safety of HR091506 extended-release tablets in patients with gout, hyperuricemia, and recurrent flares, tophi, or chronic gouty arthropathy: a multicenter, randomized, double-blind phase 3 trial",{"name":207,"slug":208},"HR091506","hr091506","Jiangsu HengRui Medicine Co., Ltd.","gout","The overall incidence of treatment-emergent adverse events (TEAEs) was similar between the HR091506 and febuxostat groups (90.5% vs 90.0%), as was the incidence of treatment-related TEAEs (65.6% vs 70.1%).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQg3IiPT9B8e_gXmV3YHydiVjsTmmnLdna66jG6MkXbl10",{"title":214,"drug":215,"company":217,"phase":148,"disease":92,"finding":218,"url":219},"Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 16-WEEK results from a head-to-head, multicentre, randomised, phase 3B study (BE BOLD)",{"name":216,"slug":216},"bimekizumab","UCB","For the primary endpoint of ACR50 at Week 16, BKZ was superior to RZB, with response in 49.1% vs 38.4% of pts (p=0.0078).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQuW1TdPP6_9_oPhziVFB72SHmPqvdNrzJYFBsGPduxgu0",{"title":221,"drug":222,"company":185,"phase":148,"disease":224,"finding":225,"url":226},"Efficacy and safety of gecacitinib, a novel pan-JAK inhibitor, in patients with active radiographic axial spondyloarthritis: Results from a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical trial",{"name":223,"slug":223},"jaktinib","ankylosing spondylitis (AS)","The ASAS20 response also significantly favored gecacitinib (69.2% vs. 21.2%, p\u003C0.0001).","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQujeBaaAmBZy51DTiHs11eVZedq7SbONsfo57uzA-L1g0",{"title":228,"drug":229,"company":133,"phase":148,"disease":92,"finding":231,"url":232},"Psoriatic Skin and Nail Outcomes With Guselkumab Treatment in Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study",{"name":230,"slug":230},"guselkumab","At W24, GUS-treated participants had -43.0% (Q4W) and -35.8% (Q8W) change from baseline (improvement) in mNAPSI compared with 16.1% (PBO), and greater response rates for achieving mNAPSI 50, mNAPSI 75, and mNAPSI 100 among GUS-treated participants.","https:\u002F\u002Fdistribution-congress.eular.org\u002Ffrom.storage?image=15rRXWmdOAJ77zPlkD-rQq7yqLt5Z7yyKa244KdqCNjZ_7E6XRbLP0ikH77cqcWz0",{"summary":234,"bullets":236},[235],"Small molecules, the most frequent modality, accounted for 54% of drug-linked abstracts, up from 46% in 2025. Non-antibody therapeutic proteins accounted for 13% of drug-linked abstracts, up from 6% in 2025. Radiopharmaceuticals (1%) were new to the top modalities compared with 2025.",[237,238,239,240,241],"GR (5% of drug-linked abstracts) was new to the top targets compared with 2025.","JAK1 was the most frequent target (11%).","Rheumatoid arthritis (RA) was the most frequent disease (25%).","Pfizer had the largest company share (9%).","DHFR accounted for 4% of drug-linked abstracts, down from 7% in 2025.",[243],{"year":244,"abstracts":245},2025,3081,{"previous_year":244,"abstracts":247,"targets":249,"modalities":259,"new_in_top_targets":266,"new_in_top_modalities":267},{"previous":245,"current":13,"change_pct":49,"direction":248},"rose",[250,252,254,255],{"name":44,"count":45,"share":20,"previous_count":251,"previous_share":75,"direction":248},15,{"name":47,"count":48,"share":49,"previous_count":137,"previous_share":69,"direction":253},"fell",{"name":51,"count":52,"share":49,"previous_count":48,"previous_share":69,"direction":253},{"name":256,"count":257,"share":113,"previous_count":258,"previous_share":20,"direction":253},"IL-6R",34,31,[260,262,264],{"name":58,"count":59,"share":42,"previous_count":261,"previous_share":137,"direction":248},312,{"name":64,"count":65,"share":18,"previous_count":263,"previous_share":30,"direction":248},40,{"name":71,"count":39,"share":20,"previous_count":265,"previous_share":113,"direction":248},22,[44],[80],[269],{"name":67,"count":68,"share":69,"previous_count":270,"previous_share":30,"direction":271},43,"flat",1793970603083]